Pursuant to subsection E of § 54.1-3443, the Board of Pharmacy is giving notice of a public hearing to consider scheduling or de-scheduling certain drugs in the Virginia Drug Control Act. The public hearing will be conducted at 9:00 a.m. on June 21, 2018 at the Perimeter Center, 9960 Mayland Drive, Suite 201, Richmond, VA 23233.
In order to conform the Drug Control Act to recent scheduling changes enacted by the Drug Enforcement Administration, the Board will:
- Add MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine) to Schedule I;
- Add Dronabinol [(-)-delta-9-trans tetrahydrocannabinol] in an oral solution in a drug product approved for marketing by the U.S. Food and Drug Administration to Schedule II; and
- Remove naldemedine from Schedule II.